Dr. Larsen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
14200 W Celebrate Life Way
Goodyear, AZ 85338Phone+1 623-207-3000Fax+1 623-207-3921
Summary
- Jeremy Larsen, MD, joined City of Hope Cancer Center Phoenix, in November 2022. A Hematologist on the hematologic malignancies team, he is especially excited to support the expansion of the hospital’s bone marrow transplant program, serving an important and unmet need in the Phoenix area. Dr. Larsen comes to City of Hope with extensive experience, not just in the treatment of blood cancers but also in cancer research, particularly in the area of immunotherapy, having presented widely on treatments of relapsed multiple myeloma and related topics and serving as a peer reviewer for Biology of Blood and Bone Marrow Transportation and other medical journals.
“My goal as a physician is to be present with my patients and build relationships with them so I can be a support throughout their cancer journey,” says Dr. Larsen. “I pride myself in communicating with transparency and compassion, meeting my patients in the middle and taking their preferences and goals into account when recommending a treatment plan.” He received his medical degree from Creighton University School of Medicine and has been in practice 8 years. He is experienced in hematologist oncology with a focus on plasma cell neoplasms including multiple myeloma, amyloidosis, Waldenstrom macroglobulinemia, and monoclonal gammopathy.
Education & Training
- Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2013 - 2017
- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2009 - 2012
- Creighton University School of MedicineClass of 2009
Certifications & Licensure
- AZ State Medical License 2017 - 2027
- NE State Medical License 2016 - 2018
- MN State Medical License 2010 - 2016
Clinical Trials
- Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma Start of enrollment: 2020 Nov 30
Publications & Presentations
PubMed
- Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma.Meletios A Dimopoulos, Magdalini Migkou, Manisha Bhutani, Sikander Ailawadhi, Anna Kalff
Leukemia & Lymphoma. 2024-12-01 - 9 citationsResponse to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma.Julia E Wiedmeier-Nutor, Madiha Iqbal, Allison C Rosenthal, Evandro D Bezerra, Juan Esteban Garcia-Robledo
Clinical Lymphoma, Myeloma & Leukemia. 2023-06-01 - Correction: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients.Rodrigo Fonseca, Mariano Arribas, Julia E Wiedmeier-Nutor, Yael N Kusne, Miguel González Vélez
Blood Cancer Journal. 2023-05-26
Journal Articles
- Utilization of Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Myeloma: A Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consen...John A Lust, Shaji K Kumar, Morie A Gertz, P Leif Bergsagel, Angela Dispenzieri, Francis K Buadi, Prashant Kapoor, Angela A Mayo, Wilson I Gonsalves, Rafael Fonseca, R..., Nature
Press Mentions
- 11 Oncologists on the MoveJanuary 23rd, 2023
Professional Memberships
- Member
- Member
- American Society for Blood and Marrow TransplantationMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: